SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings beat expectations and raised outlook, with rapid U.S. commercial growth surpassing government revenue for the first time. The shares fell despite the strong results, as traders debated whether lofty valuation and expectations leave room for further gains amid weakness in AI and technology stocks; bulls pointed to continued commercial adoption.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples quarterly earnings beat expectations, but shares came under pressure after its holiday-quarter margin outlook highlighted rising memory costs; traders also pointed to weaker China, iPad and wearables results and slowing growth. Bulls cite strong iPhone demand and a solid quarter, while bears argue the outlook and valuation leave little room for disappointment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs Q3 earnings and forward guidance are in focus after a sharp semiconductor selloff, with Intels weak outlook fueling concern about broader chip demand. Traders are divided between fears that high expectations and a weak guide could deepen the decline and hopes that strong AI and data-center results will counter the sectors pessimism.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is under pressure ahead of its quarterly earnings report, with traders pointing to a recent Bank of America downgrade and unusually heavy selling as sources of concern. The discussion is split between fears of weak results or guidance amid high rates and credit risks, and hopes that a strong report could prompt a rebound or short squeeze.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes stronger-than-expected Q3 results and raised full-year and Q4 outlook are driving attention, with traders highlighting growth in B2 cloud storage and demand tied to AI infrastructure. The reaction is broadly bullish, though some traders caution that the sharp earnings-driven move could give way to profit-taking and continued volatility.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock acquisition of Lumentum has driven a sharp selloff, with traders focused on shareholder dilution, the perceived price paid, and the long wait for the deal to close. Some see the combination of Marvells chips and networking with Lumentums optical technology as a long-term AI infrastructure opportunity, but near-term skepticism dominates.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is under pressure as investors question whether heavy AI and data-center spending will generate adequate returns, weighing on semiconductor shares. Traders are split between viewing the decline as an AI-trade unwind and seeing it as a buying opportunity, with support levels and the chance of a rebound central to the debate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm-election positioning dominates the discussion, with traders debating whether a Republican win could lift DJT or a Democratic gain would trigger a selloff. The stocks politically driven moves are also viewed skeptically by many, who describe rallies as speculative pumps and warn of further downside.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have filed an FDA application for psilocybin in major depressive disorder has stirred competition fears around Compass Pathways COMP360 program for treatment-resistant depression and contributed to a sharp selloff. Traders debate whether Usona could pressure COMP360s market position, pricing and reimbursement, while others stress the different indications and question whether the reported filing is confirmed; many are also looking to management for clarity on Compasss NDA timeline.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Rafael Holdings subsidiary has submitted an NDA for Trappsol Cyclo, another Niemann-Pick type C treatment, drawing attention to whether the FDA will accept the application despite the trials missed primary endpoint. Traders debate whether the drug could become a competitor to Zevras MIPLYFFA or offer a complementary option; the FDAs filing and review decisions remain uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?

Gileads stronger-than-expected Q3 results and raised outlook, supported by demand across its HIV franchise, are driving attention as shares reach new highs. Many traders are bullish on the business momentum, while some point to put-heavy options activity as possible hedging after the run-up.

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV...

Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week? 

Equity

Strong tobacco pricing, growing HIV drug sales and improved refining margins supported gains across the three companies. 


Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean...

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead raises its 2026 sales outlook on strong HIV growth, even as Biktarvy faces a $1.5 billion pricing headwind in 2028. What's driving its momentum?

Futures Slide As AI Reckoning Claims Amazon, Intel; Oil Jumps On Hormuz Tanker Hits

Futures Slide As AI Reckoning Claims Amazon, Intel; Oil Jumps On Hormuz Tanker Hits

 US futures slide with Nasdaq futures tumbling more than 2%, as the AI reckoning that started with Alphabet's record plunge claims two more megacaps: Amazon slides after a capex shock and the slowest...

These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results

Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.read more...

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences Q3 2026 Earnings Call Transcript

Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $2.55 up 3.24% YoY
• Reported revenue of $8.3B up 6.83% YoY
• For FY2026, Gilead raised product sales guidance to $31B, from $30.1B; product sales excluding Veklury are $30.7B, from $29.8B; diluted loss per share is now -$4.4 versus previously -$3.75.

Gileads GAAP diluted EPS was $1.94 versus $2.43; Veklury sales decreased 69% and Cell Therapy sales decreased 18%; FY2026 diluted loss per share guidance is $(4.40)-$(4.05) versus previously $(3.75)-$(3.40).

Gileads HIV product sales increased 18% to $6.2B; Trodelvy sales increased 42% to $506M and gained European Commission authorization; Bixlenvo received FDA approval for HIV treatment.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Altria reached a record $79.81 after beating Q3 earnings estimates.&nbsp;</li><li>Gilead Sciences hit a record $175.65 as strong HIV drug demand drove Q3 earnings beat.</li><li>ExxonMobil’s strong refining margins boosted Q3 profit.&nbsp;</li></ul>Altria Group (MO), Gilead Sciences (GILD) and ExxonMobil (XOM) stocks ascended to fresh 52-week highs on Friday after strong third-quarter results, improved earnings outlooks and higher shareholder returns boosted investor confidence. Strong tobacco pricing, growing HIV drug sales and improved refining margins supported gains across the three companies.&nbsp;Altria and ExxonMobil stocks gained 1% and 2%, respectively, while Gilead Sciences stock climbed 3%.&nbsp;<h2 class="st-heading-2">Altria Gains After Earnings Beat And Higher Outlook</h2><a href="https://stocktwits.com/symbol/MO">Altria stock</a> reached a record high of $79.81 after the tobacco company delivered better-than-expected third-quarter (Q3) 2026 results. Adjusted earnings came in at $1.52 per share, narrowly exceeding Wall Street's $1.51 estimate, as per Fiscal.ai.&nbsp; Revenue, excluding excise taxes, increased 3.6% from a year earlier to $5.44 billion.The company raised its 2026 earnings forecast to $5.66 - $5.74 per share and increased its stock buyback plan by another $1 billion. UBS raised its price target on MO to $83 from $79 and kept a ‘Buy’ rating. Morgan Stanley lifted its price target to $77 from $71 but maintained an ‘Equal Weight’ rating, citing weakness in traditional cigarette sales.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory.&nbsp;<h2 class="st-heading-2">Gilead Benefits From Strong HIV Drug Demand</h2><a href="https://stocktwits.com/symbol/GILD">Gilead Sciences stock</a> touched an all-time high of $175.65 after exceeding Q3 revenue and earnings expectations. Its HIV business remained a major growth engine, supported by demand for treatments such as Biktarvy and its pre-exposure prophylaxis (PrEP) portfolio.The company raised its full-year HIV business growth guidance to 12%, up from its earlier estimate of 9% to 10%. Scotiabank raised its Gilead price target to $200 from $177 and kept an ‘Outperform’ rating, suggesting a 18% upside possibility from the stock’s last close. Truist also increased its target to $181 from $158 while maintaining a ‘Buy’ rating.&nbsp;Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’.&nbsp;<h2 class="st-heading-2">ExxonMobil Rides On Refining Strength And Higher Dividends</h2><a href="https://stocktwits.com/symbol/XOM">ExxonMobil stock</a> also hit a record high of $188.50 after the energy producer reported adjusted Q3 earnings of $4.23 per share, above the $4.03 analyst consensus. Revenue totaled $110.50 billion.ExxonMobil's Energy Products division saw adjusted earnings rise to $9.05 billion, more than doubling from the previous quarter. Higher refining profits and full use of its U.S. Gulf Coast facilities helped drive the growth. Meanwhile, oil production from Guyana's Stabroek Block passed the 1-billion-barrel mark.&nbsp;The company raised its quarterly dividend by 3.8% to $1.07 per share and plans to continue its $20 billion share-repurchase program in 2027. Retail sentiment around the stock shifted to ‘neutral’ from ‘bullish’.&nbsp;So far this year, MO, GILD and XOM stocks have gained between 35% and 55%.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intc-msft-meta-dash-vz-why-retail-traders-couldn-t-take-their-eyes-off-these-stocks-last-week/cNG9irRR92a">INTC, MSFT, META, DASH, VZ: Why Retail Traders Couldn’t Take Their Eyes Off These Stocks Last Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Altria Group, Inc. is displayed on a smartphone screen.

Altria Group (MO), Gilead Sciences (GILD) and ExxonMobil (XOM) stocks ascended to fresh 52-week highs on Friday after strong third-quarter results, improved earnings outlooks and higher shareholder returns boosted investor confidence. Strong tobacco prici

Altria Group Inc.

Exxon Mobil Corp

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$170.33
Prev Close	$170.68
Open	$169.85
Dividend Yield	2.57%
50-Day Moving Average	$151.36
Beta	0.31
Avg. Volume	6.13M
PE Ratio	-54.10

52-Week High	$175.65
52-Week Low	$116.88
Market Capitalization	$211.64B
EPS (Annual)	$6.78
Price to Book	16.21
Revenue Per Employee	$1.73M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GILD Fundamentals